Invesco NASDAQ Biotechnology ETF

IBBQ

時価総額 $1.09億

The Invesco Nasdaq Biotechnology ETF carries a lower expense ratio and delivered higher total returns over the trailing 12 months than the iShares U.S. Healthcare ETF. The iShares U.S. Healthcare ETF provides broader industry diversification across the medical sector, while the Invesco Nasdaq Biotechnology ETF focuses strictly on biotechnology and pharmaceuticals.

The Fidelity MSCI Health Care Index ETF features a lower expense ratio of 0.08% and a higher dividend yield of 1.2%. The Invesco Nasdaq Biotechnology ETF has delivered a higher 1-year total return of 56.4% but carries a more significant maximum drawdown of 37.9%.

The Invesco Nasdaq Biotechnology ETF (IBBQ) offers a much broader portfolio compared to the concentrated approach of the Invesco Biotechnology & Genome ETF (PBE). IBBQ charges a significantly lower expense ratio than PBE.

Invesco Nasdaq Biotechnology ETF has a lower expense ratio but higher price volatility than Invesco S&P 500 Equal Weight Health Care ETF. Invesco S&P 500 Equal Weight Health Care ETF holds fewer stocks but uses an equal-weighting strategy to diversify across the large-cap healthcare sector.

The Health Care Select Sector SPDR Fund (XLV) carries a lower expense ratio and a higher dividend yield than the Invesco Nasdaq Biotechnology ETF (IBBQ). IBBQ has significantly outperformed on a one-year basis, but has also experienced a much more severe five-year maximum drawdown.

The Vanguard Health Care ETF offers a lower expense ratio and higher dividend yield compared to the Invesco Nasdaq Biotechnology ETF. The Invesco Nasdaq Biotechnology ETF has outperformed on 1-year total returns but carries a significantly deeper maximum drawdown.

The Invesco Nasdaq Biotechnology ETF (IBBQ) carries a lower expense ratio than the iShares Global Healthcare ETF (IXJ). IXJ offers broad global exposure across the healthcare sector, while IBBQ is concentrated exclusively in Nasdaq-listed biotechnology and pharmaceutical companies.

State Street Health Care Select Sector SPDR ETF offers a lower expense ratio and a higher dividend yield than Invesco Nasdaq Biotechnology ETF Invesco Nasdaq Biotechnology ETF provides concentrated exposure to the biotech industry but has experienced higher volatility and a deeper maximum drawdown State Street Health Care Select Sector SPDR ETF tracks a broader index of 60 healthcare stocks from the S&P 500 compared to the Invesco fund's 253 biotech holdings

Invesco Nasdaq Biotechnology ETF offers a lower expense ratio and a higher trailing dividend yield than State Street SPDR S&P Pharmaceuticals ETF. State Street SPDR S&P Pharmaceuticals ETF has delivered a higher 1-year total return and experienced a less severe maximum drawdown than Invesco Nasdaq Biotechnology ETF.

Investors are questioning the staying power of medical technology (medtech) stocks, which have fallen from grace since the COVID-19 pandemic. The starting point is to distinguish between medtech and other healthcare industries.